PARD (Poniard Pharmaceuticals) Shiller PE Ratio: (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Poniard Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Poniard Pharmaceuticals  (OTCPK:PARD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Poniard Pharmaceuticals Shiller PE Ratio Related Terms


Poniard Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Shiller PE Ratio Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PARD vs OBMP, NSPX, ATRX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poniard Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Shiller PE Ratio falls into.



Poniard Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Poniard Pharmaceuticals's E10 for the quarter that ended in Sep. 2011 is calculated as:

For example, Poniard Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2011 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2011 (Change)*Current CPI (Sep. 2011)
=-2.4/226.8890*226.8890
=-2.400

Current CPI (Sep. 2011) = 226.8890.

Poniard Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200112 -65.963 176.700 -84.699
200203 -64.787 178.800 -82.212
200206 -67.200 179.900 -84.752
200209 -105.600 181.000 -132.373
200212 24.043 180.900 30.155
200303 -38.392 184.200 -47.289
200306 43.191 183.700 53.345
200309 -28.794 185.200 -35.276
200312 -47.990 184.300 -59.080
200403 -40.792 187.400 -49.388
200406 -38.392 189.700 -45.918
200409 -35.993 189.900 -43.004
200412 -43.191 190.300 -51.495
200503 -38.392 193.300 -45.063
200506 -62.388 194.500 -72.777
200509 -22.400 198.800 -25.565
200512 -28.769 196.800 -33.168
200603 -41.600 199.800 -47.240
200606 -14.397 202.900 -16.099
200609 -8.800 202.900 -9.840
200612 -10.954 201.800 -12.316
200703 -13.600 205.352 -15.026
200706 -11.200 208.352 -12.196
200709 -8.000 208.490 -8.706
200712 -11.200 210.036 -12.099
200803 -11.600 213.528 -12.326
200806 -14.400 218.815 -14.931
200809 -14.400 218.783 -14.934
200812 -16.000 210.228 -17.268
200903 -15.200 212.709 -16.213
200906 -11.200 215.693 -11.781
200909 -11.600 215.969 -12.187
200912 -14.400 215.949 -15.130
201003 -11.600 217.631 -12.093
201006 -5.600 217.965 -5.829
201009 -5.200 218.439 -5.401
201012 -4.400 219.179 -4.555
201103 -2.400 223.467 -2.437
201106 -2.800 225.722 -2.814
201109 -2.400 226.889 -2.400

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.